SUPPLEMENTARY MATERIAL

SUPPLEMENTARY APPENDIX A: SAMPLE SEARCH STRATEGY

Database(s): Embase 1996 to 2020 Week 17 Search Strategy:

#	Searches	Results
1	exp coronavirus/	12437
2	exp Coronavirus Infections/	12279
3	((corona* or corono*) adj1 (virus* or viral* or virinae*)).tw,kw.	551
4	(coronavirus* or coronovirus* or coronavirinae* or CoV or HCoV*).tw,kw.	15440
5	("2019-nCoV" or 2019nCoV or nCoV2019 or "nCoV-2019" or "COVID-19" or COVID19 or "CORVID-19" or CORVID19 or "WN-CoV" or WNCoV or "HCoV-19" or HCoV19 or "2019 novel*" or Ncov or "n-cov" or "SARS-CoV-2" or "SARSCoV-2" or "SARSCoV2" or "SARS-CoV-2" or SARSCov19 or "SARS-Cov19" or "SARSCov-19" or "SARS-Cov-19" or Ncovor or Ncorona* or Ncorono* or NcovWuhan* or NcovHubei* or NcovChina* or NcovChinese* or SARS2 or "SARS2" or SARScoronavirus2 or "SARS-coronavirus-2" or "SARScoronavirus 2" or "SARS coronavirus2" or SARScoronovirus2 or "SARS-coronovirus-2" or "SARScoronovirus 2" or "SARS coronovirus2").tw,kw.	4488
6	(((respiratory* adj2 (symptom* or disease* or illness* or condition*)) or "seafood market*" or "food market*" or pneumonia*) adj10 (Wuhan* or Hubei* or China* or Chinese* or Huanan*)).tw,kw.	1738
7	((outbreak* or wildlife* or pandemic* or epidemic*) adj1 (Wuhan* or Hubei or China* or Chinese* or Huanan*)).tw,kw.	91
8	("severe acute respiratory syndrome*" or SARS).tw,kw.	11647
9	or/1-8	31091
10	exp *serology/	16162
11	exp *antibody/	312568
12	exp *antibody response/	7205
13	exp *seroprevalence/	5135
14	exp *serum/	19113
15	exp *assay/	93624
16	exp *immunity/	306567
17	exp *diagnosis/	1200947
18	(sero* or antibod* or serum or sera or test or tests or testing or diagnostic or diagnosis or immunity or "immune response").tw,kw.	6175013
19	(assay* adj3 sero*).tw,kw.	6289
20	or/10-19	7090637
21	9 and 20	10106
22	limit 21 to english language	9349
23	limit 22 to dc=20200101-20200331	451
24	limit 22 to dc=20200401-20200428	688

Research question addressed 3	DROP DOWN									
Research question addressed 2	DROP DOWN									
Research que stion addressed 1	DROPDOWN									
Comments										
Critical appraisal score	NUMBER Insert number number critical appraisal tool									
Assay used	FREF TEXT - Assay name - Assay name - Assay name - Assay mane - (To the extent possible - (To the extent ne - (To the extent ne									
Findings	FREE TEXT - Critical findings from the paper (probably top 3 points) - Nalings volume data entrest from papers - use this box instad to fliggl fa paper has large volumes of relevant primary data e.g. in tables and to go box espandely at drafting stage to pull relevant material in									
Relevant outcomes considered	FREE TEXT									
Study characteristics	REE TEXT to include: Human or animal study Human or animal study oppublishon size is a study oppublishon - age the study gender is a size genton u data on is agreement data on comobidities where this is given etc									
Country and setting	FREE TEXT Country - Country - Setting - I.e. bospital-based, community, based more generally (care home, school etc)									
Study de sign	DROP DOW N									
Publication type	DAAO P DOAN									
Title	RREE TEXT									
Author(s)	3 FREE TEXT									
E Ref no	ALL NUME ER	_	+	+						Η
Z	Ш									

SUPPLEMENTARY APPENDIX B: DATA EXTRACTION TEMPLATE

Supplementary figure B1. Sample data extraction template as used in the review.

SUPPLEMENTARY APPENDIX C: Approach to critical appraisal used in the review

There is a wide range of critical appraisal tools (CAT) available to support evidence assessment and synthesis work in public health and policy, but the applicability of these tools in the context of primary work in immunology is limited by (among other limitations):

- An overwhelming focus on interventional studies, rather than those concerned with exposures;
- A relative absence of tools for critical appraisal of laboratory studies, in particular experimental animal models;
- A relative absence of summative tools that enable critical appraisal of varied study types in a standardised way (rather than application of specific checklists for each study design).
- The time and resource-intensity, which limits scope for reproducible, meaningful, and robust appraisal of evidence in the context of a pandemic in which prodigious volumes of evidence are being generated.

These limitations make it very challenging to identify a coherent approach to critical appraisal that allows for evidence quality to be meaningfully compared across multiple study designs. Preliminary scoping work for this review suggested a tendency in the field of immunology to publication of narrative reviews (rather than conventional systematic reviews) without clear description of study selection criteria or critical appraisal methods. For the purposes of this review, we sought to identify a CAT that:

- Was closely related to an existing, validated tool so that it can be presented as a modification of that tool without the need for new and extended validation work;
- Was low burden and quick to use given required speed of turn-around;
- Facilitated high-level comparison of quality across diverse study designs for reporting purposes;
- Would be rapidly interpretable (ideally in the form of a traffic light system or similar) for time-pressed report readers.

Following a review of existing, generic CATs, we selected the Public Health Ontario MetaQAT 1.0 as our base tool ⁷. This is a qualitative critical appraisal tool based around 4 dimensions (relevance, reliability, validity, applicability of research findings). We made two main modifications to this tool:

- Inclusion of additional domains for publication type (pre-print, peer-reviewed etc.) and for assay type and validity.
- Introduction of a scoring and weighting system to translate findings from the tool into a traffic-light grading system for individual papers. This was <u>not</u> used to inform aggregate assessment of evidence strength against the review's over-arching research questions these assessments were made narratively.

Supplementary figure C1 shows the tool developed from this process. Reliability assessment questions were given an overall weighting of 20%, and internal external validity assessment questions 40%. The aggregated score developed from this tool was out of 10; a score of over 8 was scored "high"; 5-8 scored "medium" and scores less than 5 were "low" quality.

Domain	Assessment	Additional comments (if any)	Notes/interpretation (example prompt questions)	Question score	Weight	Weighted domain total
Publication type			Self-explanatory	0	10%	0
Assessment of relevance: is the study			Is the justification for the study clearly stated?			
relevant to the review questions?			Does it consider a similar population to the UK?	0	10%	0
				1		
Assessment of reliability (i.e. reproducib	ility)					
Is the study presented clearly?			Is the rationale clearly stated?			
			Is the conduct of the study clearly described?	0		
			Are all relevant results stated?	1		
Are the methodology and results clearly			Are inclusion/exclusion criteria clearly stated?			
described?			Was an appropriate statistical analysis approach applied?	0	20%	0
				1		
Are ethics procedures described?			Was appropriate consent sought and received?		1	
			Was the study REC approved?	0		
Assessment of internal/external validity						
Is the methodology appropriate for the			Is the design congruent with the research questions?			
scope of research and the research			Were appropriate controls sought and included?	0		
questions?				1		
Is the methodology free from bias?			Were there major sources of bias in the design, selection		1	
			of participants/controls etc?*	0		
(Where relevant) what assay was used			For validated tests, did the study team deviate in			
and was it validated?			important ways from the manufacturers' instructions?	0	40%	0
			Was a control used (e.g. for Ab measurement)?	0	4078	0
Are the conclusions explicit and			Do the conclusions logically follow-on from the results			
transparent?			presented?	0		
			•	0		
Can I be confident about the findings?			Are there major methodological flaws limiting			
Ű			interpretation of findings?	0		
Assessment of applicability:						
How applicable are the study findings to	1		Can the results be meaningfully applied to the focus			
the population(s) and public health			questions for the rapid review?	1		
questions to which the rapid review is	1		Can they be applied to the UK population (or groups of	0	20%	0
addressed?			interest?	4		
TOTAL SCORE	1			0		0

Supplementary figure C1. Sample MetaQAT template including prompt questions, and weightings applied to each of the main question domains in the tool for the purpose of quality scoring.

SUPPLEMENTARY APPENDIX D: FULL LIST OF INCLUDED STUDIES

Key - study quality assessment scoring system:

High quality: Medium quality: Low quality:

Paper	Country	Publication type	Study design	Population	Relevant Outcomes	Measurement	Findings	Quality assessment
Agrati et al ¹⁷	Italy	Peer reviewed paper	Cohort study	Human study Hospital based 18 SARS-CoV2- infected adults; RT PCR confirmation and patient demographics not stated. 9 mild, 9 severe cases included; of these, 4 mild and 4 severe were sampled longitudinally. Also, 8 healthy donors used as controls (selection procedure not described)	T cell activation profile Myeloid- derived suppressor cell (MDSC) profile	Flow cytometry: Cytoflex (Beckman- Coulter) MDSC identification with Duraclone Tubes (Beckman- Coulter)	 Compared with mild cases, more severe cases showed lymphopenia, increase in effector T cells, cytotoxic profile of T cells, and expression of CD95 on T cells, as well as higher levels of IL-6. In severe cases, MDSCs were found to constitute up to 90% of total circulating mononuclear cells while they constituted only up to 25% in mild cases. The frequency of MDSCs was observed to decrease with clinical recovery. 	Sample selection methods not clear Small sample size Validity of controls not clear
Anft et al ²²	Germany	Pre-print	Cohort study	Human study Hospital based 53 SARS-CoV2 positive adults 21 moderate, 18 severe, 14 critical cases	• Quantitative, phenotypic, and functional characteristics of lymphocytes and T-cell subsets by severity group	Flow cytometry: CytoFlex (Beckman Coulter)	 Severe and critical patients (compared with moderate) had lower CD8+ T cells, higher CD4+ T cells, and higher CD4+/CD8+ ratio An overall loss of activated and differentiated effector T cells was observed in severe and critical cases The highest responses of spike- specific T cells were in critical cases Virus-specific CD4+ T cell responses were positively correlated with antibody titres 	 Sample selection methods not clear Small sample size

Bai et al ⁶⁹	China	Peer reviewed paper	Case series	Human study Hospital based 25 SARS-CoV2 positive children, median age 11 years 8 asymptomatic, 4 mild, 13 'common' cases	• T cell profile by severity group	Not described	 Most cases had normal CD4+ T cell (23/25) and CD8+ T cell (23/25) counts and all had normal overall lymphocyte counts There were no statistically significant differences in lab results between severity groups 	 Case series design with no controls Small sample size Sample selection methods not clear Assay not stated, therefore validity unknown
Bao et al ¹⁶	Multiple	Pre-print	Systematic review with meta- analysis	Human studies Hospital based 5912 SARS-CoV2 positive patients across 35 included reports	• T cell counts by severity group	Various as per included studies; not discussed in detail	 Total numbers of B cells, T cells and NK cells were reduced in all patients with COVID-19 Severe cases had lower total lymphocytes (1.44-fold), lower CD4+ T cells (2.10-fold), and lower CD8+ T cells (2.00-fold) 	Sampling time points and intervals across included studies were not clear Assays used by included studies were not described in detail
Braun et al ⁴⁴	Germany	Pre-print	Case control study	 Human study Hospital based 18 SARS-CoV2 positive patients; average age 52.6 years, 72% male 7 mild, 5 severe, 6 critical cases; 10/18 ICU-admitted Also, 68 antibody negative healthy donors, average age 41.9 years, 31% male (selection procedure not described) 	• Frequencies and phenotypic characteristics of SARS- CoV-2 S- reactive T cells in COVID-19 patients compared to controls	Flow cytometry: MACSQuant Analyser 16 AIM assay	 Spike-reactive CD4+ T cells were present in most (83%) of COVID-19 patients, as well as in a third of SARS-CoV-2 seronegative healthy donors, though at lower frequencies. Spike-reactive CD4+ T cells in COVID-19 patients equally targeted N-terminal and C-terminal epitopes of S whereas in healthy donors, spike-reactive CD4+ T cells reacted almost exclusively to the C-terminal epitopes which have higher homology with spike proteins in HCoV Unlike for controls, spike-reactive CD4+ T cells from cases co-expressed CD38 and HLA-DR, markers of recent in vivo activation 	 Small sample size Baseline differences in case and control groups Validity of controls not clear
Carsetti et al ¹²	Italy	Pre-print	Cohort study	 Human study Hospital based 36 SARS-CoV2 positive adults Of positive cases, 20 asymptomatic, 8 mild, 8 severe cases 28 healthy, SARS-CoV2 negative adult contacts of confirmed cases 	• T cell profile in asymptomatic and other severity groups	Flow cytometry: BD FACSLyric (BD Biosciences)	 The circulating pool of T cells was not significantly changed in asymptomatic cases Increased HLA-DR+ CD4+ T cells were seen in both mild and severe cases, indicating T cell activation HLA-DR+ CD8+ T cells were increased only in severe cases 	Sample selection methods not clear

Chandrashekar et al ⁵¹	Animal study	Peer reviewed paper	Basic Science	Animal study Laboratory based 9 Rhesus macaques initially inoculated and then re- challenged with SARS-CoV2 • 3 further Rhesus macaques as controls, challenged once with SARS-CoV2	 Cellular immune responses to S proteins, by IFN-γ release S protein specific CD4+ and CD8+ induction after initial challenge IFN-γ release at re- challenge 	IFN-γ ELISpot (Cellular Technologies Limited)	 Cellular immune responses to spike peptides were demonstrated in most subjects on day 35. There was a trend toward lower responses in lower dose groups. Both spike-specific CD8+ and CD4+ T cell responses were observed Increased IFN-γ responses were observed by day 7 after re-challenge 	• Small sample size • Animal model
Chen and Sang et al ³⁴	China	Peer reviewed paper	Cohort study	Human study Hospital based 548 SARS-CoV2 positive patients with known outcome (discharged or deceased) • 345 mild or moderate, 155 severe, 48 critical cases • T cell subset analysis in 141 cases	• T cell profile across severity groups	Flow cytometry: specific device not stated	 Non-survivors showed reductions in peripheral CD3+, CD4+ and CD8+ T cells at the point of admission For more severe cases there was a trend towards lower CD3+, CD4+ and CD8+ counts, with the percentage of CD8+ T cells significantly lower in severe or critical patients compared to mild or moderate patients Non-survivors had significantly elevated leukocytes generally, and neutrophils specifically, with an elevated neutrophil/lymphocyte ratio, as well as an elevated platelet/lymphocyte ratio 	 Sample selection for T cell assays not clear Single T cell measurement only (at admission) Assay not fully described
Chen and Zhang et al ⁷⁰	China	Peer reviewed paper	Case series	Human study Hospital based 12 SARS-CoV2 positive children, median age 14.5 years 20 SARS-CoV2 positive adults as controls	• T cell profile across children and adult cases	Not described	 Paediatric cases had higher total T cells, CD8+ T cells and B cells than adult cases Most children had normal white cells counts; 2 cases had lymphopenia 	 Case series, scope for selection bias Small sample size Sampling timings and intervals not clearly described Cellular assays not described
Diao et al ¹³	China	Peer reviewed paper	Case control study	Human study Multi-centre hospital based 522 SARS-CoV2 positive patients, both adults and children 20 were ICU- admitted cases; more in-depth analysis was done on 212 non-ICU cases from one centre of which 151 were mild/moderate, 40	T cell profile across severity groups and age groups T cell exhaustion phenotypes Relationship between cytokine concentration and T cell count	Flow cytometry: LSR Fortessa (BD Biosciences)	 Lower T cell counts were observed in COVID-19 cases generally, with relatively lower counts in ICU-admitted cases compared to non-ICU admitted cases, as well as in perished and severe/critical cases compared to mild/moderate cases within the non-ICU group An age-dependent reduction in T cells was observed, with lowest counts in older groups (of three age categories) T cells had higher PD-1 and Tim-3 expression in COVID-19 cases, and this increased with clinical progression TNF-a, IL-6, and IL-10 were significantly 	Unclear sample selection of subset undergoing detailed T cell characterisation Relatively few controls and unclear validity, regarding possible exposure to SARS- CoV2

				severe, and 13 critical cases (as per Chinese national severity definitions), and also including 8 patient deaths • Also, 40 healthy controls who attended hospital for routine examination during the same period • Detailed T cell phenotypic analysis in 14 patients and 3 controls			increased in COVID-19 cases, with levels in ICU patients significantly higher than in non- ICU patients. Concentration of these three cytokines was negatively correlated with total T cell counts.	
Dong et al ⁶⁶	China	Peer Reviewed paper	Case control study	Human study Hospital based 18 SARS-CoV2 positive adults, mean age 58.39 years, 61.11% male, mean hospital stay 18.22d	 Dynamic T cell profiles for prolonged (≥ 15d) and non-prolonged (<15d) nucleic acid positive patients Correlation between T cell count and duration of nucleic acid positivity 	Flow cytometry: specific device not stated	 Significantly higher T cells and B cells were seen at discharge than at diagnosis for all 15 COVID-19 patients who had both results available Patients with nucleic acid-positivity for ≥ 15 days had significantly decreased lymphocytes and T cell total and CD4+ and CD8+ subset counts compared to those who remained positive for <15 days There was a significant negative correlation between lymphocytes and T cells at diagnosis, and the RNA-positivity duration 	Recruited only those with existing flow cytometry data, therefore scope for selection bias Small sample size Flow cytometry device not stated
Du et al ⁶⁸	China	Peer reviewed paper	Cohort study	Human study Hospital based 182 SARS-CoV2 positive children, median age 6 years, 65.9% male 43 with history of 'allergic disease' (inc. allergic rhinitis, asthma, atopic dermatitis, urticaria, food/drug allergy);139 with no such history	• T cell profile on admission between those with and without history of allergic disease	Not described	 CD8+ T cell percentage was significantly lower in the non-allergic patients than in the allergic patients The lymphocyte subset counts were not significantly different between the allergic and non-allergic patients, or between patients with and without pneumonia Allergy was not a risk factor for COVID-19 and it did not influence disease severity or clinical course 	 Sample selection methods not clear Small sample size T cell assays not described
Duan et al ⁷³	China	Pre-print	Case control study	• Human study • Hospital based • 616 SARS-CoV2 PCR or antibody positive adults; median age 64, 57.5%	• Lymphocyte profile comparison between the two groups of confirmed	Not described	• Compared with confirmed cases, the seronegative suspected cases had a significantly higher lymphocyte count and relative proportion of CD8+ lymphocytes	• Sample selection methods and, SARS-CoV2 PCR testing process, and therefore designation of

				female, median 13 days since symptom onset • Also, 35 SARS- CoV2 antibody negative but suspected cases (symptoms suggestive of COVID- 19); median age 55, 57.1% female, median 8 days since symptom onset	COVID-19 cases, and seronegative suspected COVID-19 cases			groups not clear • Days from symptom onset substantially different between two groups, significant potential for bias • T cell assay not described • Overall methodology not clear and high potential for bias
Gallais et al ⁴¹	France	Pre-print	Cohort study	 Human study Hospital based Cluster of 7 families with 9 COVID-19 recovered index cases, median age 45, 50% male, median symptom duration 7 days Also, 8 antibody negative contacts of index cases (6/8 were symptomatic within 1- 7d of index cases) and 10 antibody negative healthy donors (not known to be exposed to COVID-19 cases) were used as controls. Blood samples collected 47-69 days post-symptom onset 	• Virus- specific T cell responses between index cases, contacts and controls	IFN-γ ELISpot	 All index patients showed SARS-CoV2-specific IFN-γ responses to at least 4 epitopes (S1, S2, N and M). 6/8 contacts showed virus-specific responses to at least one epitope (structural and/or accessory); 5/6 of these had been symptomatic The frequency of reactive T cells in 5 contacts was similar to index patients and higher than in healthy controls Half of the controls showed some T cell responses to 1-2 SARS-CoV2 epitopes (mostly S2), but of much lower magnitude than cases and contacts All participants, except one control, showed T cell responses against HCoV (229E and OC43) 	 Unclear PCR testing processes, may have affected differentiation of index and contact cases Small sample size Validity of healthy donor controls not clear
Ganji et al ⁶³	Iran	Peer reviewed paper	Case control study	 Human study Hospital based 25 SARS-CoV2 positive patients admitted to ICU 25 healthy controls of similar age and sex distribution (selection procedure not described) 	T cell profile in COVID-19 cases compared to healthy control T cell subset protein expression by mean fluorescence intensity	Flow cytometry: BD FACSCalibur (BD Biosciences) Mean fluorescence intensity (MFI) evaluation	 The difference in CD4/CD8 ratio, CD4+ T cell frequency, CD8+ T cell frequency, and CD4+ MFI was not significant between cases and controls There was a significant increase of CD8+ MFI in cases vs controls WCC, lymphocyte, and platelets were significantly reduced in ITU cases vs controls 	 Sample selection methods not clear Small sample size Only ICU- admitted patients, no lower severity cases included Validity of healthy controls not clear

Gimenez et al ³⁸	Spain	Peer reviewed paper	Case series	Human study Hospital based 19 SARS-CoV2 positive cases, 6 suspected cases; medial age 62 years, 56% male, T cell sampling at a median of 27 days from symptom onset	Virus- specific T cell profiles across two groups Association between virus- specific T cells and antibodies	Flow cytometry: FACScanto (BD Biosciences) Intracellular cytokine staining assay	 Ten patients (40%) had responses targeting S1 and M proteins SARS-CoV-2-reactive IFN-γ-CD8+T cells developed at comparable rates irrespective of disease severity. However, the two patients who died did not have detectable responses. No correlation was found between levels of reactive CD8+T cells and titres of spike- specific antibodies amongst confirmed cases 	 Sample selection methods not clear Small sample size No control group Assay validity unclear (adapted protocol from CMV assay)
Grifoni et al ⁴²	USA	Peer Reviewed paper	Case control study	 Human study Hospital based 20 SARS-CoV2 positive adults, median age 44, 55% female 70% mild, 20% moderate, 10% severe cases 20 unexposed controls, median age 31, 65% female (samples collected prior to SARS-CoV2 emergence) Samples collected a median of 26 days post symptom onset 	 Virus- specific T cell responses between cases and controls Association between T cells and antibody titres Correlation between CD4+ and CD8+ T cells 	Flow cytometry: specific device not stated Activation induced marker (AIM) assay Intracellular cytokine staining assay	 Higher spike-specific CD4+ and CD8+ T cell responses were detected by AIM in cases vs controls Spike-specific CD4+ T cell responses positively correlated with the magnitude of anti-RBD IgG levels Anti-spike IgA levels also correlated with spike-specific CD4+ T cells Virus-specific CD4+ and CD8+ T cell responses correlated well with each other 	• Small sample size • Baseline differences between cases and controls
Hartman et al ⁷⁴	Animal study	Pre-print	Basic Science	Human study Hospital based 6 adult male African Green monkeys; average age 3.5 years Inoculated with SARS-CoV2 via aerosol (4/6) or mucosal (2/6) exposure	• Dynamic cellular response profiles in SARS-CoV2 challenged animals by route of infection	Flow cytometry: specific device not stated	• Relative proportions of proliferating CD4+ and CD8+ T cells increased transiently between 2-11 days after infection in most subjects, with sustained increases in proliferating CD8+ T cells in the mucosally- infected group.	 Animal model, validity of inoculation routes not clear Small sample size No control group

He et al ³²	China	Peer reviewed paper	Case control study	 Human study Hospital based 204 SARS-CoV2 positive patients 135 non-severe, 69 severe cases (as per Chinese national COVID-19 pneumonia classification criteria) Subset of 15 severe (7 recovered and 8 died) and 14 non- severe patients included in a longitudinal analysis 	T cell profile in severe vs non-severe cases Dynamic changes in T cells over course of admission (subset of 15 severe and 14 non-severe patients) Sensitivity and specificity of T cell subset counts for disease severity	Not described	 Significant increases in WBC cells and neutrophils, and decreases in lymphocytes were observed in severe cases; also CD3+, CD4+, CD8+, were significantly lower in severe cases From the onset of pneumonia, T cells gradually increased during admission in non- severe patients, and remained higher than in the severe group. In the improved subgroup of severe patients, T lymphocytes began to increase after 15 days and normalised after 25 days. In contrast, T lymphocytes in the dead sub-group of severe patients continued to fall until death. Counts of CD3+, CD4+, and CD8+ T cells showed high sensitivity and specificity for disease severity 	T cell assay not described Small sample size for longitudinal measurements
Hu et al ⁷⁵	China	Pre-print	Cohort study	Human study Hospital based 211 SARS-CoV2 positive patients; average age 47.5, 39.2%	Association of immune cell counts and cellular ratios, with presence of antibodies	Not described	• There was no significant difference in WCC, T and B lymphocytes, CD4+ and CD8+ T cells, and CD4+/CD8+ ratio between the IgM / IgG seropositive and seronegative groups.	Sample selection methods not clear T cell assay not described
Jiang et al ²⁵	China	Peer reviewed paper	Cohort study	Human study Hospital based 32 confirmed cases (13 mild, 10 severe, 9 critical) and 18 age- and sex-matched controls.	T cell profile over the disease course (and by severity)	Flow cytometry: FACSCanto II flow cytometer (BD, USA).	CD8+ T cells in COVID-19 cases, particularly critical cases were highly activated with possibly higher cytotoxic potential The absolute numbers of lymphocytes, total T cells, CD8+ T cells, and NK cells were restored in the remission group Expression of CD38, HLA-DR on CD8+ T cells decreased in the remission group indicating reduced CD8+ T cell activation and cytotoxic potential	Selection process for study participants and controls unclear Study received research ethics committee approval but process for individual participant consent are unclear

Jiang et al ¹⁴	China	Peer reviewed paper	Case control study	Human study Hospital based 103 SARS-CoV2 positive patients; median age 46, 56.3% males * 86 mild/moderate, 17 severe ICU- admitted cases • Also, 13 healthy individuals with no infectious disease diagnosis and no known exposure to COVID-19 were used as controls (selection procedure not described)	T cell profile in cases vs controls and across severity groups T cell counts over disease course and by nucleic acid positivity (subset of 23 cases only)	Flow cytometry: Cytomics FC 500 (Beckman Coulter)	 Cases had a slight decrease in CD4+T cells and significant decrease in CD8+T cells, with raised CD4/CD8 ratio Severe cases showed significant decreases in CD3+T, CD4+T, and CD8+T cells counts compared to mild/moderate patients There was no significant difference in proportion of Treg cells between mild/moderate and severe cases Counts of CD3+, CD4+ and CD8+T cells dramatically recovered in most patients who became RNA-negative but there was no significant difference for persistently RNA- positive cases 	 Sample selection methods not clear Small sample size for longitudinal measurements Validity of controls not clear
Juno et al ⁴⁷	Australia	Pre-Print	Case control study	Human study Community based n=41 patients who had recovered from COVID-19, median age 59 (IQR:54-65), of which 43% were female, and 27 healthy adult controls Participants sampled a median of 36 days post symptom onset	B and T cell response according to disease severity Plasma neutralisation activity	Activation Induced Marker Assay + ELISA	 Frequency of T follicular helper (TFH) cells specific to HKU1 (an endemic human coronavirus) was higher amongst COVID-19 convalescents than uninfected controls Expanded populations of spike-specific memory B cells and circulating (c)TFH cells detected High plasma neutralisation activity was also found to be associated with increased spike- specific antibody, but notably also with the relative distribution of spike-specific cTFH subsets. 	Sample size small Inclusion and exclusion criteria are unclear
Kang et al ⁷⁶	South Korea	Peer Reviewed paper	Case control study	Human study Hospital based 12 cases, of which 4 severe and 8 mild cases; 5 healthy control volunteers	Leucocyte response according to disease severity	Flow cytometry	 No significant difference in CD4 and CD8 cell counts between groups in first week. In second week, CD4+ count 396.5 ± 101.9 in the severe group vs. 684.3 ± 82.0 in the mild group (p=0.062). CD8+ T cell, 250.9 ± 50.1 in the severe group vs. 445.0 ± 76.1 in the mild group (p=0.174) Higher indicators of T cell proliferation observed in severe group vs mild group over the course of the study. Activated T cells tended to be higher in the severe group than in the mild group at the third week, especially in terms of PD-1 expression (mean ± SEM, the severe group compared with the mild group. Frequencies (%) of perforin and granzyme B expression in both CD4+ and CD8+ T cells were higher in the severe group than in the mild group. 	Very small sample size Process for selection of participants unclear Controls were included in the study, but it is unclear whether they were matched to the main participant group

Laing et al ⁸	UK	Pre-Print	Cohort study	 Human study Hospital based 63 hospitalised COVID-19 cases, 55 healthy controls. Cased were sampled variously on the day of admission or between 3-6 days post-admission. 	B and T cell response according to disease severity	Flow cytometry	 T cell cytopenia observed across all disease categories, with decreases in CD4 and particularly CD8 T cells. Gamma delta T cells severely depleted across all disease categories. CD4 TH17.1 substantially depleted in severe patients Putatively terminally differentiated CD8 TEMRA cells were 'significantly' depleted across patients Consistent with their activation, there were approximately 10-fold increases in the percentage of CD4 and CD8 T cells in either G1 or S-G2/M phases of the cycle in patients, in contrast to healthy controls where over 98% of cells comprise G0 cells in transit. 	• Relatively small sample size
Le Bert et al ⁴³	Singapore	Pre-Print	Cohort study	 Human study Hospital based PBMC samples from 24 individuals who had recovered from mild-severe COVID- 19, 23 individuals who had recovered from SARS-CoV-1 and 18 samples from people not exposed to SARS CoV-2 	T cell response against nucleocapsid proteins and NSP proteins on SARS- CoV-1/2	IFN-γ ELISpot assay cross- referenced with intracellular cytokine staining (ICS)	 A clear population of NP specific CD4 and/or CD8 T cells were detectable in 7/9 subjects tested. COVID-19 convalescents developed T cells specific to regions that were also targeted by T cells of SARS recovered subjects NP-specific T cells were detected in some of the SARS-CoV-1/2 unexposed individuals, although the pattern of T cell reactivity was different. NSP7/13-specific T cells were detected in 9 out of 18 (50%) SARS-CoV-1/2 unexposed donors. 	• Small sample size • Method of participant and control selection unclear (assumed to be convenience- based) - no evidence that controls were matched
Li et al ⁷⁷	China	Peer reviewed paper	Cohort study	 Human study Hospital based 127 paediatric cases enrolled between January and March 2020 with confirmed COVID-19 (confirmed using RT- PCR) Median age 6 years (IQR: 1-9 years, range: 2 months to 15 years), ratio of M:F = 1.3:1. 2 of the 127 patients ended up in ITU. 125 of the patients were discharged during the lifetime of the study. 	Lymphocyte subsets	Flow cytometry: FACSCanto)	 Low CD4+/CD8+ ratio observed in 18.3% of participants CD4+CD25+ T lymphocyte <5.0 % was statistically associated with clinical diagnosis of pneumonia (OR 1.93, 95% CI 1.04-3.61, P=0.038) 	 Method of participant selection unclear (assumed to be convenience- based) Assays stated but not clear whether these were validated No detail on mode by which participant consent was sought (in a paediatric study)

Liu and Fang et al ⁶⁴	China	Pre-print	Cohort study	Human study Hospital based 340 confirmed COVID-19 cases (310 discharged, 30 deaths), median age 57	T cell subset counts	Flow cytometry: FACSCalibur flow cytometer (BD Biosciences)	 T lymphocyte subsets – total T cells, T helper cells and suppressor T cells – were significantly lower among patients who ultimately died than those who survived to discharge. Multivariate logistic regression modelling (outcome = death) identified predictors including age (OR 1.05, p 0.04), underlying disease status (OR 3.42, p 0.02), Helper T cells on the log scale (OR 0.22, p 0.00), and TH/TS on the log scale (OR 4.80, p 0.00). 	No control group recruited Unclear how participants were selected (assumption is that this was convenience- based) T cell testing approach status but no detail given on validation status or use of controls
Liu and Han et al ⁴⁰	China	Pre-print	Case control study	 Human study Hospital based 128 patients in total 37 non-severe SARS ('persistently positive') CoV-2 patients + 37 non-severe SARS CoV (positive on assessment) patients + 54 healthy controls Mean age of participants (SD) = 5.09 (4.71); male n = 23, female n =17 Median age 53, 67% of the sample were male 	CD3+, CD4+ and B cell counts	Flow cytometry: FACS Aria III cytometer (BD bioscience, USA)	 Among persistently positive (PP) patients, absolute numbers of CD3, CD4 and NK were significantly higher than in the positive on assessment (PA) group. Compared to those persistently positive with a negative PCR after a further 7 days, those with a positive result had a significantly lowerCD3, CD4, CD8 and B cell count (p=0.001, =0.005, =0.003 and =0.003 respectively). Furthermore, amongst those who converted from persistently positive to negative, their CD3, CD4, CD8 and B cell counts increased significantly between the last positive and first negative tests (p=0.001, =0.002, =0.009 and =0.008 respectively). No significant differences between the PP group and the healthy control group, but patients from both groups had increased numbers of CD3+T cells, CD4+T cells, and NK cells compared to those from the PA group. In addition, PA patients had significantly lower frequency of B cells compared with healthy subjects. 	 Sampling based on clinical presentation – but controls were included and were matched (age and sex) Assay validity unclear

Liu and Li et al ³⁵	China	Peer reviewed paper	Cohort study	Human study Hospital based 27 "mild" and 13 "severe" COVID-19 cases with a mean age of 48.7, and 62.5% female overall (narrow majority male in the severe category)	T cell subset counts and percentages	Lymphocyte test kit (Beckman Coulter Inc., FL, USA). Human Th1/2 cytokine kit II (BD Ltd., Franklin lakes, NJ, USA).	 There were significant decreases in the counts of T cells, especially CD8+ T cells, as well as increases in IL-6, IL-10, IL-2 and IFN-g levels in the peripheral blood in the severe cases compared to those in the mild cases. T cell counts and cytokine levels in severe COVID-19 patients who survived the disease gradually recovered at later time points to levels that were comparable to those of the mild cases. 	Small sample size No control group recruited Unclear how participants were selected (assumption is that this was convenience- based)
Liu and Liao et al ³³	China	Peer reviewed paper	Case control study	 Human study Hospital based 76 patients, 46 with mild disease, 30 with severe 	CD4+, CD8+ count Interleukin levels		 CD4 and CD8 count significantly lower in severe disease than in mild disease (P<0.001 for both). IL-2R, IL-8 and IL-6 significantly higher in severe disease than in mild disease (p = 0.022, 0.026 and 0.012 respectively). Lymphocyte, CD4+T lymphocyte, and CD8+T lymphocyte counts in the severe group were significantly lower than they were in the mild group (Z=-5.889,-4.932, and-5.505, respectively; p<0.001). 	
Liu and Long et al ⁶⁷	China	Peer reviewed paper	Cohort study	 Human Hospital based 39 hospital patients with lymphocyte subsets measured on admission. Median age 53yrs (IQR: 41- 61), 51% female, 46.2% severe or critical infection. 38.5% had comorbidities. 	T cell subset counts	Not described	 T cells, CD4+ T cells, and CD8+ T cells were all statistically higher in patients who had a mild infection, timely (<5 days PSO) hospitalization, and fast recovery (all p<0.05). Patients whose RT-PCR turned negative within 14 days after onset showed higher levels of both T and B cells (p<0.05). CD8 cells were higher in those without comorbidities than in those with (p=0.046) 	 No control group recruited Unclear how participants were selected (assumption is that this was convenience- based) T cell testing approach status but no detail given on validation status or use of controls

Liu and Wang et al ⁵⁹	China	Peer reviewed paper	Case series	 Human Hospital based 154 cases among adults Stratified by severity: moderate group (total 49, male 26 and female 23), severe group (total 61, male 34 and female 27), critical group (total 44, male 24, female 20) The average age of the moderate group, the severe group, and the critical group is 63 ± 13, 63 ± 14, and 65 ± 15 y, respectively. 	T cell counts	Flow Cytometer BNII (Becton Dickinson).	 CD3+ and CD4+ lower than normal range in 78% and 76% of participants respectively. CD3+, CD4+ and CD8+ values lower in critical group compared to severe group (statistically significant - p<0.001), but no difference was found between the moderate and severe groups 	 No control group recruited Unclear how participants were selected (assumption is that this was convenience- based) T cell testing approach status but no detail given on validation status or use of controls
Luo et al ³⁶	China	Peer reviewed paper	Case control study	 Human Hospital based 1018 diagnosed COVID-19 patients from a retrospective clinical cohort presenting to two centres in China - divided into a survivor cohort (n=817) and a non- survivor quasi control (n=201) Mean age 61, 51% male overall, but 66% in the non-survivor group; some 36% of the study sample overall had diagnosed hypertension 	T cell subsets; cytokine levels	CLIA: Immulite 1000, DiaSorin Liaison, Italy,or Cobas e602, Roche Diagnostics. Flow cytometry.	 CD3 +, CD4+ and CD8+ counts significantly lower in non-survivors than in survivors. The absolute count of CD8+ was below 100 cells/µL in non, less than half of the total number of surviving cells. CD8+ cell count lower 96.89 vs. 203.98 cells/µL,P<0.001 (for difference) for non-survived vs survived CD8+ T cell counts <165 cells/µL independently associated with mortality (OR=5.930; 95%CI, 3.677-9.562;P<0.001), after adjusting for confounding factors including age, sex, and underlying diseases 	Risk of bias in selection of participants based on presentation to hospital setting No matching performed for control group T cell measurement approach described but nature of controls used unclear
Mann et al ¹⁸	UK	Pre-print	Cohort study	 Human Hospital based Recruitment of participants from 4 acute centres in Manchester. 73 patients in total, of which 49 could be stratified based on disease severity Control group of 18 	T cell counts; subsets; cytokine levels	Flow cytometry - in-house.	 Reduced T cells in acute phase (across CD4 and CD8 with slight decrease in CD4+ T cells in severe cases Both T cell subsets showed signs of activation in cases, more striking in CD8+ T cells, did not track with disease severity, and highly variable Higher perforin expression in CD8+ T cells in cases compared to healthy individuals Increase in T cells prior to discharge (linked with recovery) in 70% of cases irrespective of 	Risk of bias in selection of participants based on presentation to hospital setting No matching performed for control group T cell measurement approach described

				females and 9 males recruited a neighbouring university and NHS trusts (age range 28- 69) • Overall median age was 61 (IQR 51- 71)and 63% were male			severity • Other data only presented in charts • Unclear if statistical analysis performed on cases vs controls	but nature of controls used unclear
Marcos- Jimenez et al ⁷⁸	Spain	Pre-print	Cohort study	 Human study Hospital based 276 patients stratified according to illness severity in accordance with WHO scheme 19 healthy controls 	T cell subsets and counts	Flow cytometry - in-house.	CD8+ decreased in severe cases, but CD4 similar in cases and controls cTFH proportion significantly increased with severity: median 0.51 in healthy donors to 1.7 % in severe (this difference was statistically significant)	Participant inclusion and exclusion criteria are not clearly stated Control group was recruited but no information on characteristics of this group or mode of recruitment is provided T cell measurement approach described but nature of controls used unclear
Mazzoni et al ⁹	Italy	Peer reviewed paper	Cohort study	 Human study Hospital based 30 adult patients with SARS-CoV2 confirmed by RT- PCR; 30 adult controls (healthy) also recruited Median age of the patients was 70 years (range 36-85 years), the mean age was 65.9 years. 60% of the cases were male. The mean age was 67.9 years for women. Immunological analysis performed on average 9.2 days PO 	T cell subsets and counts	Flow cytometry - in-house.	 Absolute CD3+ lower in cases than controls (including lower subsets of CD4+, CD8+ and CD56+) (statistically significant) Reduction more pronounced in CD8+ (cytotoxic) than CD4+ (helper) CD4+/CD8+ ratio higher in cases than controls (statistically significant) Absolute numbers of CD3+ lower in ICU compared to non-ICU, only for CD4+ subset (not CD8+ or CD56+) 	• Risk of bias in selection of participants based on hospital presentation

Minervina et al ⁴⁹	Russia	Pre-print	Basic Science	Human study Hospital based 2 adult patients, 1 male and 1 female, recruited who were RT-PCR positive for SARS-CoV2 and were symptomatic	CD4+ and CD8+ count; measurements of cell reactivity	Flow cytometry: FACS Aria III	 Identified groups of T cell clones which contracted from day 15 to 45 with recovery and further group which expanded from day 15 to day 37 Both donors developed IgG response by day 30 and remained positive to end of follow up (day 45) 	Very small sample size Method for selection of participants unclear No controls included Method for measurement of T cell response unclear
Neidleman et al ⁵⁰	USA	Pre-print	Case series	Human study Hospital based 4 adult patients who tested positive for SARS-CoV2 via RT- PCR and recovered from mild infection, 2 uninfected blood donors as controls	CD+ and CD8+ counts T cell phenotyping	Flow cytometry - in-house.	 Spike specific CD4 and CD8 cells producing IFN present in cases and not controls, and were phenotypically diverse Different characteristics of CD8 cells identified and reported in detail in paper - narrative 	Very small sample size Method for selection of participants unclear Method for measurement of T cell response unclear
Ni and Tian et al ³⁵	China	Peer reviewed paper	Case series	 Human study Hospital based 27 adult patients, 14 male and 13 female, age 33-83 and median 60 years, all of whom were confirmed to have COVID-19 by RT-PCR All defined as having severe pneumonia, with requirement for supplemental O2 	IL-1β, IL-2R, IL-8, IL-10, and TNF-α levels T cell counts and subsets	IMMULITE 1000 Immunoassay system (Siemens Healthcare Diagnostics Products Limited) Electrochemilu minescence immunoassay (Cobas E601; Roche, Basel, Switzerland) Flow cytometry	 Pre-treatment T lymphocytes were decreased in 76.2% of participants (mean 720+/- 328), CD4+ decreased in 57.1% (mean 472+/-280) and CD8+ decreased in 85.77% (mean 219 +/- 113) - all statistically significant Post treatment T lymphocytes in normal range for all participants - (mean 1080+/-341), CD4 mean 678+/-255, CD8 mean 355+/-138) - all statistically significant 	Risk of bias inherent in case series based on clinical presentation alone (and given absence of a control group) No formal statistical evaluation of immune response according to potential confounders was made

Ni and Ye et al ⁷⁹	China	Peer reviewed paper	Case control study	Human study Hospital based 14 adults with confirmed COVID-19 (age range 32-68) and 6 healthy controls (samples from the US) - all adults who had had the disease were convalescents	T cell counts and subsets	Flow cytometry - in-house.	 No difference in percentages of T cells between cases and controls The numbers of NP-specific T cells (indicating that the development of neutralizing antibodies may be correlated with the activation of anti-viral T cells) (statistically significant) 	Small sample size Method for selection of participants unclear although controls were recruited and are adequately described
Odak et al ⁸⁰	Germany	Pre-print	Cohort study	 Human study Hospital based 30 adult patients hospitalised (24 male, 6 female) with COVID-19 60 age and gender- matched healthy controls Age range 39-91 	• T cell counts - total and subsets	BD TruCount TM Flow cytometry: BD FACS Lyric + FCSExpress (De Novo Software).	 Compared to healthy controls, mild-disease and severe-disease COVID19 cases displayed generalised lymphopenia and reduced T-reg cell numbers. Lower counts of NK, NKT, and CD8+ T cells were observed in cases with severe but mild disease Decrease in the proportion of memory/effector CD4 T cells in severe disease compared to mild disease Decrease in naïve and increase in effector/memory and central memory CD4 and CD8 T cells observed in convalescent cases 	 Sample selection and inclusion criteria not clearly described No control for confounders beyond age No report of an Fc block and live- dead marker in counts panel Appears that the comparison between memory and naïve T cells was performed on non-Tregs only
Ouyang et al ⁶⁰	China	Peer reviewed paper	Case control study	 Human study Hospital based 11 patients in total, of which 5 mild, 6 severe/critical Median age 63, 5 male, 6 female, 3 with an underlying chronic condition 	• T cell counts • Plasma cytokine levels	Luminex bead based MILLIPLEX® assay for the cytokines T Cell proportions - CyTOF based analysis	 IL-10 level significantly varied with disease progression and treatment. T cell subsets were generally reduced in severe patients, CD8+ T cell counts much slower to normalise than CD4+ 	REC approved but unclear about consent Selection process unclear, analysis unclear in parts No control group Small sample size Lack of clarity in relation to statistical results, including number of tests performed

Patterson et al ³⁰	USA	Pre-print	Non- randomised controlled trial	 Human study Hospital based 10 critically ill individuals All had significant pre-existing co- morbidities 	T cell percentages • CD4/CD8 T cell ratio • Plasma cytokine levels	Customized 13- plex bead-based flow cytometric assay (LegendPlex, Biolegend, Inc) CytoFlex flow cytometer (Beckman Coulter Life Sciences, Indianapolis, IN). Kaluza version 2.1 software.	 Levels of IL-6 significantly higher in critically ill patients compared to patients with mild or moderate COVID-19 Post Leronlimab treatment, marked restoration of CD8+ T cells and normalization of CD4/CD8+ T cell ratio observed 	 Sample selection and inclusion criteria not clearly described Small sample size Characteristics of controls not provided
Payen et al ³⁹	France	Pre-print	Cohort study	 Human study Hospital based 15 adult COVID-19 inpatients followed longitudinally (for overall changes over time) (specific n=5 for function T cells), ICU patients Median age 66 [IQR 60-72], 80% male 	• T cell subsets over time • Functionality of T cells over time	Flow cytometry: BD FACSLyric™ Clinical System (BD Biosciences) Navios flow cytometer for IFN (Beckman Coulter)	 CD8+ counts fell to a minimum by days 11- 14 post-onset of symptoms (p=0.03) with recovery thereafter Later nadir for CD4+ (days 19-23, not statistically significant) observed, with no significant change in the CD4/CD8 ratio overall throughout the follow-up period N specific CD4 T cells less numerous than S specific CD4 T cells A decrease in CD4 and CD8 T cells was observed in severe patients, however no disruption of the CD4/CD8 ratio is shown (polyfunctional SARS-Cov-2-specific CD4 T- cells were present and functional, whereas virus-specific CD8 T-cells were less frequent and not efficient). Isolation of SARS-COv2- specific T cells showed that after in vitro stimulation CD4 T cells were more capable of secreting cytokines (IFNg, TNFa, IL-2) with higher TNFa. IL-2 positive cells. 	 Sample selection and inclusion criteria not clearly described Small sample size No controls

Peng et al ⁴⁶	UK	Pre-print	Case control study	Human study Hospital based 42 adult patients hospitalised with COVID-19 who subsequently recovered, including 28 mild and 14 severe cases - days PO 42.5 for mild and 41.5 for severe Mild - median age 53.8, IQR 47.6-60.9, 60% male, n=28 Severe - median age 60.6, IQR 44.9-74.1, 64% male, n=14 19 controls - median age 46, 8 male	Frequency of T cells, correlated with disease severity T cell epitope characteristics	BD LSR Fortessa (BD Biosciences) flow cytometer and FlowJoTM v.10 software IFN-γ ELISpot assays	 Positive correlations (all statistically significant) between spike specific, RBD and NP specific antibody titres and overall T cell and spike specific T cells A higher magnitude and broader breadth of overall T cell responses observed in severe cases compared to mild, in particular responses to spike, membrane, ORF3 and ORF8proteins (all statistically significant) More T cell responses detected to spike- and M/NP found to be mediated by CD8+ (rather than CD4+) T cells in mild compared to severe Functional memory responses identified Six immunodominant epitope clusters identified and showed low similarity to epitopes from other coronaviruses. 	• Selection of controls not clearly described
Qin et al ¹⁵	China	Peer reviewed paper	Case control study	 Human study Hospital based 452 hospitalised patients with COVID- 19, 286/452 clinically severe infection. Median age 58yrs (IQR 47-67), 52% men, 44% had chronic disease. Lymphocyte subsets were analysed in 44 patients with COVID- 19 on admission 	• Lymphocyte subset response according to severity.	Phorbol 12- Myristate 13- Acetate (PMA)/ionomy cin-stimulated lymphocyte function assay Flow cytometry: FACSCanto flow cytometer	 T cells counts were lower in severe cases (461.6 vs 663.8/μL; P = .027) when compared with the non-severe group. This pattern occurred for multiple T cell subtypes. The total number of B cells, T cells, and natural killer (NK) cells were significantly decreased in pa-patients with COVID-19 (852.9/μL), which was more evident in the severe cases. Both helper T (Th) cells (CD3+,CD4+) and suppressor T cells (CD3+,CD8+) in patients with COVID-19 were below normal levels, and the decline in Th cells was more pronounced in severe cases. 	No controls used Small sample size for lymphocyte assessments
Shomuradova et al ⁴⁵	Russia	Pre-print	Case control study	Human study Mixed hospital and community 31 COVID-19 Convalescent patients, - samples collected days 14-49 Control group of 14 health donors - samples collected pre- COVID	• T cell response in convalescent patients	IFNγ secretion assay (Milteny biotech) IFNγ ELISpot assay (ELISpot kit) ELISA (theromoscienti fic)	 Some healthy COVID-19-naive donors had T cells specific to SARS-CoV-2 antigens and in particular spike-protein No clear association observed between T-cell response magnitude and HLA genotype of the donor, time post disease onset, disease severity or age. A mild correlation between the magnitude of T-cell and humoral response was observed (for anti-RBD IgG and CD8+ T-cell response r=0.386 p=0.0321) The magnitude of CD8+ and CD4+ response magnitudes were interdependent Among convalescent donors, significantly more CD4+ cells in expressed HLA-DR and CD38 - a similar tendency for CD8+ T cells 	 Sample selection process not clearly described Small sample size

							 was observed, although the difference was not significant. Most SARS-CoV-2 specific CD4+ belonged to the TCM subpopulation, whereas most CD8+ T cells displayed a TTE and TEM phenotype 	
Thieme et al ²³	Germany	Pre-print	Cohort study	 Human study Hospital based 28 COVID-19 patients with moderate (8), severe (10) and critical (10) manifestations All critical patients were male; age range for the sample as a whole 26-91 	• T cell counts and percentages	CytoFlex flow cytometer (Beckman Coulter)	 Stimulation with M-protein overlapping peptide pools induced the highest frequencies of reactive CD4+ T cells. In comparison to S- and N-reactive CD4+ T cells , higher frequencies of M-reactive CD4+ T cells were detected. These cells expressed effector molecules e.g. interleukin (IL)-2, interferon γ (IFNγ), tumour necrosis factor α (TNFα), and granzyme B (GrzB) Exposure to the N-protein induced the lowest responses 	 Sample selection and inclusion criteria not clearly explained Small sample size No controls used Unclear presentation of methodology and findings
Vabret et al ³	Multiple	Peer reviewed paper	Narrative review	• Methodology for selecting papers for review not disclosed	• T-cell response	N/A	 Drastically reduced numbers of both CD4 and CD8 T cells observed in moderate and severe COVID-19 cases. Severity of lymphopenia, most prominent for CD8 T cells in patients requiring intensive care, appears to correlate with COVID-19- associated disease severity and mortality Now widely documented that a decrease in peripheral blood T cells is associated with disease severity and inflammation . Multiple studies find raised numbers of activated CD4 and CD8 T cells, trending toward an exhausted phenotype in persistent COVID-19 infection, accompanied by ongoing and upregulated expression of inhibitory markers and potential reduced polyfunctionality and cytotoxicity 	Search strategy not described Critical appraisal not discussed Quantitative synthesis not attempted

Varnait et al ⁸¹	Sweden	Pre-print	Case control study	Human study Hospital based 20 hospitalised COVID-19 patients, 7 with co-morbidities. Blood samples collected a median of 5 days POS • 7 healthy control donors	• T-cell response	BD Trucount Tubes (BD Biosciences) BD Accuri Plus flow cytometer BD LSRFortessa flow cytometer BD FACSDiva Software (BD Biosciences)	 Decreased absolute numbers of lymphocytes (CD45+) and T cells (total CD3+ and CD3+ CD8+ cells) observed in cases compared to controls No significant decrease of B cells (CD19+) or CD4+ T cell observed. Higher frequencies of activated CD4 and CD8 T cells measured 	 Sample selection process not clearly described Small sample size Assay validity not clear
Wang and Su et al ⁸²	China	Peer reviewed paper	Case control study	 Human study 12 patients, split by clinical condition at presentation i.e. mild, n=4; severe, n=5; and critical, n=3 Mean age was 58 years old, 42% were men, and 57.1% were women; 42.9% had chronic diseases such as hypertension, diabetes, and cardiovascular disease 	T cell counts	Mass cytometry (CyTOF)	 Proportions of B cells, CD4+CD8+double-positive T cells, naïve CD4+T cells, and TGF-β+CD28-naïve CD4+T cells where generally increased in infected patients versus health donors CD8+T cells, irrespective of their the effector, naïve, or memory phenotype, declined over the duration of disease progression. The same pattern was observed for NK cells, monocytes, myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs) - that is increase the observed during progression from mild to severe infection followed by decline when progressing to a critical condition. Proportions of dendritic cells (DCs), macrophages, CD4+T cells, and TGF-β+CD28-naïve CD8+T cells were found to be higher in the mild compared to the severe group 	Sample selection process for both cases and controls not clearly described Small sample size Validity of controls not clear No statistical analysis done
Wang, Hou and Luo et al ²⁴	China	Peer reviewed paper	Case control study	Human study Hospital based 65 SARS-CoV2 positive patients, mean age 57, 57% male Illness classified as milla (n=30), severe (n=20), and extremely severe (n=15)	• T cell counts	Flow cyometry: FACSCanto flow cytometer (BD Biosciences). FACSCanto clinical software (BD Biosciences).	 Absolute numbers of CD4+ T cells, CD8+ T cells and cells declined with increased illness severity of illness Markers of activation, e.g. HLA-DR and CD45RO, expressed on CD4+ and CD8+ T cells were raised in severe and extremely severe compared with mild cases 	 Small sample size for more severe disease groups No controls used Application of inclusion criteria not fully described

Wang, Hou and Yao et al ⁶⁵	China	Peer reviewed paper	Case control study	 Human study Hospital based 157 COVID-19 patients Controls - 95 survived and 62 deceased patients. No difference in groups between age and gender 	• T cell counts • CD4/CD8 T cell ratio	Flow cytometry - no further details provided	 Non-survivors had lower CD4+ counts only evident in middle and late stages of disease compared to survivors. A lower CD4/CD8 ratio was also observed non-survivors. 	 Sample selection process not clearly described Methodology not fully described Statistical analysis not done
Weiskopf et al ⁴⁸	Netherlands	Pre-print	Case control study	 Human study Hospital based 10 SARS-CoV2 positive patients; average age 58.9 years, 60% male 10/10 with previous ARDS and ICU admission, later 2 deceased and 1 discharged Also, 10 unexposed controls (samples collected prior to SARS-CoV2 emergence) 	Virus- specific T cell responses, phenotypes and cytokine production in severely ill COVID-19 patients compared with unexposed controls	Flow cytometry: BD FACSLyric (BD Biosciences) AIM assay	 CD4:CD8 ratios were increased in COVID- 19 patients recovering from ARDS when compared to controls SARS-CoV-2-specific CD4+ and CD8+ T cells were detected in 100% and 80% of COVID-19 patients, with activation defined by cell surface expression of CD69 and CD137. Strongest T cell responses were directed to the surface glycoprotein (spike, S) SARS-CoV-2-specific CD4+ and CD8+ T- cells appear in blood of ARDS patients in the first two weeks post onset of symptoms, and their frequency increases over time SARS-CoV-2-specific CD4+ T-cells in blood typically had a central memory phenotype (based on CD45RA and CCR7 expression), whereas the majority of virus-specific CD8+ T-cells was identified as CCR7- effector memory (TEM) or terminally differentiated effector (TEMRA) Low levels of SARS-CoV-2-reactive T-cells were detected in 20% of the unexposed controls 	 Sample selection methods not clear Small sample size

Wen et al ⁸³	China	Peer reviewed paper	Case control study	 Human study Hospital based 10 COVID-19 patients (divided into early recovery stage (ERS) group and late recovery stage (LRS) group) All males Age range 30–80 years old, with a median of 58 years old in ERS, a median of 49 years old in LRS and a median of 55 years old in heathy controls 	• T cell counts • CD4/CD8 T cell ratio	No details provided on methods of T cell enumeration	CD4+ T cells and CD8+ T cells decreased significantly and expressed high levels of inflammatory genes in the ERS group	 Sample selection process not clearly described Small sample size No controls used
Xu et al ¹⁰	China	Peer reviewed paper	Case control study	• Human study • Hospital based • 187 adult patients hospitalised with COVID-19	• T-cell response	Flow cytometry - no further details provided	 All patients, at admission, had significantly decreased lymphocyte counts (median = 0.88, IQR 0.55-1.27 mg/L) All patients, particularly the severely and critically ill including dead patients, displayed a significant reduction in T cell subsets counts with increased concentrations of SAA and CRP compared to normal value The median counts of lymphocyte, CD3+ T-cell, CD4+ T-cell, and CD8+ T-cell in critically-ill patients, were almost decreased to a third of median counts detected in mildly-ill patients, and equal to nearly half of the median counts observed in severely-ill patients 62 patients had T cell subsets measured more than once, including mild-ill (n=18), severe-ill (n=22) and critically-ill (n=22). After 5-14 days post admission, T cell subsets counts slightly increased than above that observed at disease onset. Total T cell counts <500/µl, CD3+ counts <200/µl, CD4+ or CD8+ counts <100/µ as well as B cell counts <50/µL, were significantly associated with risk of in-hospital death, however this is only on univariate analysis 	• Sample selection process not clearly described

Yang et al ⁸⁴	China	Pre-print	Case control study	Human study Hospital based 38 COVID-19 cases. Median age 39.06±4.26 years , 23 men, and 15 women 18 healthy controls	• T cell counts • Plasma cytokine levels	Flow cytometry: FACSCanto II flow cytometer (BDBiosciences)	 Based on CD25 expression, mild activation of CD4+ T cells was detected in COVID-19 patients with a stronger activation in CD8+ T cells observed. No correlation with age was measured 	 Sample selection process not clearly described No characterisation of study population Methodology not fully described
Zhang and Zhou et al ³¹	China	Pre-print	Cohort study	 Human study Hospital based 222 Patients. Median age 62. 48.2% male and 39.2% patients with severe disease. 194 recovered from diseased and 59 recovered by anti- viral supported therapy. Serum samples collected at admission and convalescence (35 days) 	T-cell counts Cytokine levels	Human Cytokine Standard Assays panel (ET Healthcare, Inc., Shanghai, China) and Bio- Plex 200 system (Bio- Rad, Hercules, CA, USA)	 Severe patients had higher proinflammatory cytokines levels including IL-2, IL-6 and IL-10 where detected in patients with severe disease compared to those with non-severe disease. Severe patients with severe disease and high neutrophil-to-lymphocyte ratio displayed higher proinflammatory cytokines levels including IL-2, IL-6 and IL-10, and decreased CD4+ T cell count (p<0.05). 	 Selection of cases not clearly described Sampling process and intervals not consistent across the study Assay validation unclear
Zhang et al ²¹	China	Peer reviewed paper	Case series	 Human study Hospital based 6 children varying in age from 7-131 months 5 healthy controls 	• T cell percentages	Aria II flow cytometer (BD), Flow Jo v10 software (BD)	 Percentage of CD3+, CD4+, and CD8+ T cells were comparable between cases and controls. No difference in CD45RA and CCR7 expression in CD4+ and CD8+T cells was observed between four infected paediatric cases and five controls 	 Sample selection process not clearly described Small sample size Methodology not fully described No controls used

Zhou et al ¹¹	China	Peer	Cohort	 Human study 	T-cell counts	No details	Correlation was found between total	Small sample size
		reviewed	study	 Hospital based 		provided on	lymphocyte and CD4 T-cell count	• Use of non-
		paper		• 17 patients. Disease		methods of T	• In the "aggravation" group of patients,	standard clinical
				progression measured		cell	CD4+T cell count was significantly lower	classifications
				at day 7 post		enumeration	compared to the "non-aggravation" group	Assays not
				admission. 11 women			(P=0.034). No significant difference was	clearly described
				and 6 men between 18			observed between the 2 groups in relation to	
				and 70 years.			the CD8+T cell count.	
				 5 pts with 			CD4+T cell count was positively correlated	
				'aggravated disease'			with total lymphocyte count (r=0.940,	
				and 12 with 'non			P<0.0001)	
				aggravated'				
				[aggravation:				
				temperature is higher				
				than previous				
				measurement,				
				respiratory symptoms				
				more severe, and				
				lesion(s) on lung CT				
				is larger in size than				
				previously measured]				

SUPPLEMENTARY APPENDIX E: PRISMA CHECKLIST

Section/topic	#	Checklist item	Reported on page #
TITLE	<u>.</u>		
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
ABSTRACT			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	3
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of what is already known.	4
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	5-6
METHODS			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	5
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	5-6
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	5
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	Suppl Appendix A
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	5-6
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	6
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	5, Suppl Appendix B
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5-6, Suppl Appendix C
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5-6
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I^2) for each meta-analysis.	5-6 (narrative synthesis)

Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	14-15
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta- regression), if done, indicating which were pre-specified.	N/A (narrative synthesis)
RESULTS			

Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6, Figure 1		
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	Suppl Appendix D		
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	Suppl Appendix D		
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	N/A (narrative synthesis)		
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	N/A (narrative synthesis)		
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	14-15		
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	N/A (narrative synthesis)		
DISCUSSION					
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	13-14		
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	14-15		
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	16		
FUNDING					
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	18		